Rucaparib Could Extend Survival for Uterine Cancer Patients
FRIDAY, March 22, 2024 -- An already approved cancer drug could be an effective treatment for women with advanced, recurring uterine cancer, a new clinical trial shows.
Rucaparib, which belongs to a class of drugs called PARP inhibitors, extended...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Clinical Trials | General Medicine | Women